Combination treatment of bicalutamide and curcumin has a strong therapeutic effect on androgen receptor-positive triple-negative breast cancers
Triple-negative breast cancers account for approximately 15–20% of breast cancer patients. Due to lack of expression of estrogen receptor, PR and human epidermal growth factor receptor 2 in triple-negative breast cancers, there are no targeted therapies available for these cancers. Therefore, a major research priority is to find potential therapeutic targets. Androgen receptor is present in 80–90% of all breast cancers, including 55% of estrogen receptor-α–negative cancers and 12%–35% of triple-negative breast cancers. Androgen receptor stimulates growth and survival in triple-negative breast cancer cells. Treatment with bicalutamide, an androgen receptor antagonist, has a good benefit for AR+ triple-negative breast cancer patients. AR+ triple-negative breast cancer cells were treated with curcumin or bicalutamide alone or in combination of both together. Cell growth, apoptosis and Wnt signaling pathways were examined. We found that curcumin dramatically suppressed Wnt signaling pathway in AR+ triple-negative breast cancer cells. Curcumin treatment inhibited androgen receptor protein expression in AR+ triple-negative breast cancer cells. Combination treatment of curcumin and bicalutamide has a robust increase in apoptosis. Furthermore, the combination treatment suppressed the growth of AR+ triple-negative breast cancer cells more effectively than with the single drug alone. Our data indicate that androgen receptor inhibition is a potential therap...
An imaging technique that combines F-18 FDG PET and MRI was able to pinpoint...Read more on AuntMinnie.comRelated Reading: SNMMI 2020: How nuclear medicine handled COVID-19 SNMMI 2020: Medical students key to the specialty's future PET, MRI uncover women's predisposition to Alzheimer's PET/MRI shows inflammation link to mitral valve prolapse Biomarkers on PET, MRI show breast cancer risk
Publication date: Available online 13 July 2020Source: Pathology - Research and PracticeAuthor(s): Jie Zhang, Sujie Zhang, Xiaoyan Li, Fan Zhang, Lei Zhao
Conclusion: The current study clearly demonstrates that the Momordica charantia aryl and seed extracts have the potential to exert its cytotoxic effect on breast cancer cells by a mechanism involving inhibition of EGFR and EGRF related pathways with the induction of apoptosis. The overall finding demonstrates that this plant, especially seed extract, could be a potential source of new anticancer compounds for possible drug development against cancer.
CONCLUSION: None of the six proteins proved to be suitable prognostic factors for OS and DSF in patients with TNBC. PMID: 32266539 [PubMed - indexed for MEDLINE]
CONCLUSION: Knowledge of initiation and growth of tumors with known effects of neo-ATs suggest that intermittent endocrine ATs may achieve the same results as EATs but with improved quality of life and survival because of fewer side effects and better compliance. The challenge for developments of repeated ATs becomes: how short is short enough. PMID: 32472445 [PubMed - indexed for MEDLINE]
Abstract PURPOSE: Few studies have investigated the relationship between vitiligo and risks of various types of cancers, especially those other than skin cancer. Conventional observational studies are susceptible to potential confounders and inverse causation. With a Mendelian randomization approach, we were able to evaluate the causality between vitiligo and different cancer risks. METHODS: 37 vitiligo-related single-nucleotide polymorphisms identified by the published genome-wide association studies were used as instrumental variables in our study. Summary data of individual-level genetic information were o...
CONCLUSIONS: HER2Bi- or EGFRBi-armed CART19 exhibited specific cytotoxicity against multiple HER2+/EGFR+/CD19- tumor targets in overnight and long-term serial killing assays. CART19 showed improved survival and were resistant to exhaustion after prolonged repeated exposure to tumor cells. PMID: 32449004 [PubMed - indexed for MEDLINE]
Women with breast cancer are more likely to die of cancer after experiencing...Read more on AuntMinnie.comRelated Reading: House subcommittee delays USPSTF mammo recommendation New breast cancer risk model includes 93 relationships Earlier breast screening benefits women with childhood cancer Some cancers found earlier after Medicaid expansion How mammography screening succeeded in Sweden
Publication date: Available online 13 July 2020Source: Journal of Herbal MedicineAuthor(s): Nazila Darvishi, Vahid Yousefinejad, Mohammad Esmail Akbari, Mohammad Abdi, Nariman Moradi, Shoaleh Darvishi, Yadollah Mehrabi, Ebrahim Ghaderi, Yasaman Jamshidi-Naaeini, Bayazid Ghaderi, Seyed Hossein Davoodi
Authors: Osman MA, Antonisamy WJ, Yakirevich E Abstract Triple negative breast cancer (TNBC) is a heterogenous and lethal disease that lacks diagnostic markers and therapeutic targets; as such common targets are highly sought after. IQGAP1 is a signaling scaffold implicated in TNBC, but its mechanism is unknown. Here we show that IQGAP1 localizes to the centrosome, interacts with and influences the expression level and localization of key centrosome proteins like BRCA1 and thereby impacts centrosome number. Genetic mutant analyses suggest that phosphorylation cycling of IQGAP1 is important to its subcellular locali...